Clinical Trial Update: Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rifaximin for the secondary prevention of recurrent spontaneous bacterial peritonitis in cirrhotic patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Spontaneous Bacterial Peritonitis

Drugs mentioned

• XIFAXAN (rifaximin)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Spontaneous Bacterial Peritonitis | Phase 3 | Status: WITHDRAWN